Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Last trade$2.52
Day change-$0.47 (-15.72%)
Day range$2.45 – $3.19
Volume144,023
Market cap$111M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$111.21M
Price / earnings
—
Price / book
-0.64×
Price / sales
14.72×
EV / sales
41.61×
EV / EBITDA
-9.57×
Profitability
Earnings per share
-$3.30
Return on assets
-145.44%
Return on equity
70.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.27×
Current ratio
0.12×
Quick ratio
0.12×
Cash ratio
0.1×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$26.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARMP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.17M
$2.51M
$789K
$1.09M
$1.16M
$2.17M
$491K
$1.24M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$3.17M
$2.51M
$789K
$1.09M
$1.16M
$2.17M
$491K
$1.24M
Selling, general and administrative
$3.72M
$5.24M
$3.46M
$3.43M
$3.11M
$2.62M
$3.25M
$3.32M
Research and development
$6.83M
$7.59M
$6.11M
$6.07M
$5.82M
$6.39M
$5.43M
$8.45M
Total operating expenses
$10.55M
$12.82M
$9.57M
$14.91M
$8.94M
$9.01M
$8.68M
$11.77M
Operating income
-$7.38M
-$10.31M
-$8.79M
-$13.82M
-$7.78M
-$6.84M
-$8.19M
-$10.54M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$54.86M
$74.14M
-$115.35M
-$124.3M
-$26.68M
-$16.3M
-$6.53M
$2.6M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$54.86M
$74.14M
-$115.35M
-$124.3M
-$26.68M
-$16.3M
-$6.53M
$2.6M
Net income attributable to common shareholders
$42.64M
$74.14M
-$115.35M
-$124.3M
-$26.68M
-$16.3M
-$6.53M
$2.6M
EBITDA
-$6.81M
-$9.72M
-$8.33M
-$7.99M
-$7.41M
-$6.48M
-$7.81M
-$10.16M
Basic earnings per share
$1.15
$2.02
-$3.16
-$3.42
-$0.74
-$0.45
-$0.18
$0.07
Diluted earnings per share
-$0.24
-$0.27
-$3.16
-$9.52
-$0.74
-$0.45
-$0.20
$0.02
Recent news
Company coverage with links to the original publishers.
Armata Pharmaceuticals reported a Q3 loss of $0.24 per share, beating consensus estimates of $0.57 loss by 57.90%. Revenue reached $3.17 million, significantly surpassing estimates by 252.33% compared to $1.16 million year-ago. However, the stock has underperformed the market, declining 38.1% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Liquidia Corporation (LQDA) reported Q3 2026 earnings of $0.80 per share, beating consensus estimates of $0.77, with revenues of $225.3 million exceeding expectations by 20.72%. Despite the strong earnings beat and 38.8% year-to-date stock gain, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The stock is expected to underperform the market in the near term.
Starling Oncology reported a Q3 loss of $0.13 per share, missing EPS expectations of $0.07 loss by 85.71%, though the company beat revenue estimates with $169.77 million versus consensus of $168.41 million. The stock has gained 94.9% year-to-date but received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Krystal Biotech reported Q3 2026 earnings of $2.05 per share, beating consensus estimates of $1.84 per share, with revenues of $127.34 million exceeding expectations by 2.16%. However, despite the earnings beat and 34.8% year-to-date stock gain, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance relative to the market.
DelveInsight's 2026 report highlights a robust pipeline for pseudomonal infections treatment with 10+ active pharmaceutical companies developing innovative therapies. Key players including Armata Pharmaceuticals, Respirion Pharmaceuticals, and AstraZeneca are advancing promising candidates like AP-PA02, RSP-1502, and AZD0292 through clinical trials. Recent developments include Respirion's successful Phase Ib completion of RSP-1502 and Armata's encouraging Phase II results for AP-PA02, addressing the significant unmet medical need in treating antibiotic-resistant Pseudomonas aeruginosa infections.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.